Literature DB >> 10404700

Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia.

A Soupart1, M Ngassa, G Decaux.   

Abstract

BACKGROUND: Inappropriate correction of chronic hyponatremia could lead to major neuropathological sequelae. In man, the risk of brain myelinolysis increases strikingly when correction of the serum sodium exceeds 10-15 mEq/l/24 h. No treatment is actually available for this iatrogenic brain injury. However, recent experimental data showed that rapid reinduction of the hyponatremia greatly reduces the incidence of brain damage and death in case of serum sodium overshooting. SUBJECTS AND METHODS: We tested this rescue manoeuver in a 71-year-old woman with nausea, confusion and severe (SNa 106 mEq/l) chronic hyponatremia related to thiazides. It was associated with hypokalemia (SK: 3.2 mEq/l).
RESULTS: Treatment with isotonic saline produced inappropriately high SNa correction level of +21 mEq/l after the first 24 h. After initial improvement, the neurological status deteriorated after 72 h. Rapid reinduction of the hyponatremia was then ordered. Administration of hypotonic fluids (by oral and i.v. route) combined with dDAVP induced a prompt decline in the SNa (-16 mEq/l/14 h) with a final gradient of correction of deltaSNa +9 mEq/l. This manoeuver was well tolerated without untoward effects. The natremia then progressively normalized and the patient completely recovered without neurological sequelae.
CONCLUSION: Hypotonic fluids may be safely administered to decrease the natremia after excessive correction of hyponatremia for potential prevention of myelinolysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404700

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  23 in total

Review 1.  Therapeutic Relowering of Plasma Sodium after Overly Rapid Correction of Hyponatremia: What Is the Evidence?

Authors:  Helbert Rondon-Berrios
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-10       Impact factor: 8.237

Review 2.  Preventing neurological complications from dysnatremias in children.

Authors:  Michael L Moritz; J Carlos Ayus
Journal:  Pediatr Nephrol       Date:  2005-08-04       Impact factor: 3.714

3.  Management of hyponatremia in various clinical situations.

Authors:  Michael L Moritz; Juan C Ayus
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

4.  DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia.

Authors:  Anjana Perianayagam; Richard H Sterns; Stephen M Silver; Marvin Grieff; Robert Mayo; John Hix; Ruth Kouides
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

5.  Possible causes of central pontine myelinolysis after liver transplantation.

Authors:  Jun Yu; Shu-Sen Zheng; Ting-Bo Liang; Yan Shen; Wei-Lin Wang; Qing-Hong Ke
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

6.  Treatment response in osmotic demyelination syndrome presenting as severe parkinsonism, ptosis and gaze palsy.

Authors:  Sanihah Abdul Halim; Nur Aida Mohd Amin
Journal:  BMJ Case Rep       Date:  2018-10-21

7.  Desmopression is an effective adjunct treatment for reversing excessive hyponatremia overcorrection.

Authors:  Kamel A Gharaibeh; Matthew J Craig; Christian A Koch; Anna A Lerant; Tibor Fülöp; Eva Csongrádi
Journal:  World J Clin Cases       Date:  2013-08-16       Impact factor: 1.337

Review 8.  Tumor-related hyponatremia.

Authors:  Adedayo A Onitilo; Ebenezer Kio; Suhail A R Doi
Journal:  Clin Med Res       Date:  2007-12-17

Review 9.  Disturbances of sodium in critically ill adult neurologic patients: a clinical review.

Authors:  Martin Tisdall; Matthew Crocker; Jonathan Watkiss; Martin Smith
Journal:  J Neurosurg Anesthesiol       Date:  2006-01       Impact factor: 3.956

Review 10.  Central pontine myelinolysis and the osmotic demyelination syndromes: an open and shut case?

Authors:  Pyari Bose
Journal:  Acta Neurol Belg       Date:  2021-03-13       Impact factor: 2.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.